Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. - Wikidata - awgldk - TriplyDB

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

http://www.wikidata.org/entity/Q37697034

about

The GDNF Family: A Role in Cancer?ER-positive breast cancer cells are poised for RET-mediated endocrine resistance.A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.RET rearrangements are actionable alterations in breast cancer

P2860

Q47137356-3408C7BC-D450-4ED7-99A2-56017FC35D11 Q53699376-31518DB3-45B0-46AB-94DB-017E0A48B324 Q54118050-9B92D69B-D0B8-46DB-8CEF-441037C24FA7 Q59136613-A12BEE39-8450-47A5-947A-750DAB5EE9CD

P2860

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

http://www.wikidata.org/entity/Q37697034

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@en

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@nl

type

label

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@en

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@nl

prefLabel

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@en

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@nl

P1433

Q37697034-2D813797-882F-4E8E-86B3-233788BF44D9

P1476

Q37697034-32CC7240-C04F-4C6D-B161-DDDC2EA98923

P2093

Q37697034-230BA166-5480-4AE0-80E5-BB3A10574F16

Q37697034-8E1BE85C-85E5-447C-B7DC-5A39BAE190D8

Q37697034-8E49552E-822D-4236-896A-595C9442066F

Q37697034-B47467BF-BACA-424D-B2C8-5F9EA34CDA43

P2860

Q37697034-0EC47A55-77E6-4085-8D24-D3C3CE6C878E

Q37697034-131D80DE-54CF-4F97-A358-922BC69DB171

Q37697034-15D660D6-0947-469F-AC60-790198EF2D39

Q37697034-1C693AB6-ED87-42CA-B1B5-B13E26C8F338

Q37697034-490924A8-BA3D-4521-8928-685EA7F1F81A

Q37697034-4F977FFE-D7B6-43E2-8045-01268C99911E

Q37697034-578700E3-AD22-490F-9230-27026E1C9523

Q37697034-5D80EA75-E0E7-4198-82B1-781B8EB05078

Q37697034-78AD1224-79AC-4689-8A36-16A75ACD586E

Q37697034-7A2EF790-B77C-45C5-A7CE-CE24FBE9384B

P304

Q37697034-01CD5561-F160-43AC-B687-DE1A1AE774E7

P31

Q37697034-2FAAF486-014E-4F04-8F70-3481094C5AFA

P356

Q37697034-3D552C28-8A74-4272-A61E-31B48405735C

P407

Q37697034-FA6272E8-B9F0-4CAD-A52C-6782AEF81FD1

P433

Q37697034-3088D85E-59F1-44C5-A0A6-C40C4E8805C5

P478

Q37697034-68957216-AFF7-42BB-B500-777A265C8804

P50

Q37697034-3CE8197F-CDB5-4CDA-B0C8-8BC31A7E665D

Q37697034-DDD462A5-D38A-4421-AF68-56999E2846CD

Q37697034-F92A4856-B076-4AFA-B357-CE5B7F047A36

P577

Q37697034-B39C9EED-DD0C-4645-A2E7-359A319EB747

P698

Q37697034-2A88A3AB-6251-4AEB-BC96-5DD9F05791E7

P921

Q37697034-CB40BD10-F857-4B49-AC9E-80C08B00F334

P932

Q37697034-DDCD7BA9-0BD6-4031-A6E7-BEA70CE7D7AC

P356

ONCOTARGET.11826

P1433

P1476

Targeting the receptor tyrosin ...... tive breast cancer xenografts.

@en

P2093

Antony Fearns

http://www.w3.org/2001/XMLSchema#string

Lesley-Ann Martin

http://www.w3.org/2001/XMLSchema#string

Paola Chiarugi

http://www.w3.org/2001/XMLSchema#string

Paola Francica

http://www.w3.org/2001/XMLSchema#string

P2860

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells.

DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.

Targeted therapies for ER+/HER2- metastatic breast cancer.

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

P304

80543-80553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.11826

http://www.w3.org/2001/XMLSchema#string

P407

P433

49

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Elena Andreucci

P577

2016-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27602955

http://www.w3.org/2001/XMLSchema#string

P921

P932

5348339

http://www.w3.org/2001/XMLSchema#string